Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 244
- Locations
- 2
- Primary Endpoint
- Vaccine uptake following the introduction of the pamphlet
Study Overview
Brief Summary
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients hospitalized at medical departments of the hospital who are on the day of discharge
Exclusion Criteria
- •Egg ellergy
- •Previous allergic reaction to influenza vaccine
- •Pregnancy
- •Cognitive disability
Outcomes
Primary Outcomes
Vaccine uptake following the introduction of the pamphlet
Time Frame: On the same day, upto 24 hours
Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
Secondary Outcomes
- Vaccine uptake in high and low risk group patients following the introduction of the pamphlet(On the same day, upto 24 hours)
Investigators
Burcu Isler
Principal investigator
SB Istanbul Education and Research Hospital